Join collection
Hello, welcome to our official website!

New Situation . New Vision . New Opportunity . New Challenge

Background
On March 19, 2019, the World Intellectual Property Organization (WIPO) published its global intellectual property report 2018.Asian innovators filed more than half of their international patent applications through WIPO for the first time in 2018, with significant growth in China, India and South Korea, the report noted. As a technology-intensive industry, pharmaceutical industry attaches great importance to patent application and intellectual property protection. In recent years, the size of the global pharmaceutical market has maintained a steady growth, with China, South Korea, India and other emerging markets presenting a rapid growth momentum. With the acceleration of economic globalization, more and more Chinese pharmaceutical companies are entering the European and American markets, and multinational pharmaceutical companies are also increasing their investment in emerging markets.
Due to the different intellectual property policies of different countries, the strategic layout of global intellectual property, the differences of pharmaceutical intellectual property policies of Asia-pacific countries, the patent review process, litigation procedures and Generic drug patent strategy have gradually become the hot spots of the pharmaceutical intellectual property industry. In this context, the Asia-Pacific Pharma Intellectual Property Leader Summit will be held in Beijing on November 14-15, and will attract more than 400 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.
  • Contact us for details
    65%
    Two - Day Conference, Two - days Networking Lunch, Coffee Breaks, Electronic Copy of Presentation PPTs, Introduction guests
  • Contact us for details
    22%
    Engage with 400+ participants in pharmaceutical intellectual property field, Meet with senior decision makers from startups to global multinational corporations; Enhance brand awareness
  • Contact us for details
    13%
    Insight into industry trends; Discuss with senior decision makers from domestic and international enterprises about the hottest topics, and present your innovative ideas; Make voices through online and offline media; Enhance brand awareness
  • Interpretation of Policy-Pharmaceutical Intellectual Property Policies and Regulations under the New Situation
    Day one morning
    2019.11.14
  • Pharmaceutical R&D Innovation and IP Protection -- Global Vision
    Day one afternoon
    2019.11.14
  • Case Sharing of Invalidity, Infringement, Litigation
    Day two morning
    2019.11.15
  • Opportunities and challenges for generics companies under the new situation
    Day two afternoon
    2019.11.15




1.         Interpretation of Pharmaceutical Intellectual Property Policies and Regulations under the New Situation

2.         Judicial innovation promotes the development of pharmaceutical intellectual property

3.         The Unitary Patent Court and Brexit -- Opportunities and challenges for drug companies in the new political and legislative environment

4.         European, American and Japanese Medical Patent Examination Cases and its implications for Domestic Pharmaceutical Companies

5.         Intellectual Property Management Experience in Multinational Pharmaceutical Companies, Patent Layout Strategy, Litigation Strategy

6.         The global layout of intellectual property of emerging market pharmaceutical companies, under the background of globalization

7.         Patent cliff coming, patent infringement suits case proliferates, how does Pharmaceutical companies deal with

8.         Trade frictions between China and the United States are escalating, patent litigation in the United States and its implications for Chinese pharmaceutical companies

9.         The Strategy of Indian Generic Drug Companies in R&D and Pre-PA

10.     Litigation of Generic Drug--- How to avoid the Patent Trap

11.     Hotspot analysis of pharmaceutical patent invalidation cases in China, Japan and South Korea

12.     Opportunities and challenges of pharmaceutical companies under patent extension compensation system---Encouraging competitions, not stifling innovation


Interpretation of Policy-Pharmaceutical Intellectual Property Policies and Regulations under the New Situation

Opening and Chairman’s Welcome Address

Medical Policy Interpretation under the Background of Patent Law Amendment

------ In December 2018, The Executive Meeting of The State Council deliberated and adopted the draft amendment to the patent law, which has been reviewed for the first time by the NPC and is expected to be completed within this year. In particular for innovative drugs added invention patent protection extended the exceptional provisions.

The innovation of Judicial Mechanism Promotes the Development of Pharmaceutical Intellectual Property

Networking Coffee Break

WIPO’s Patent Cooperation Treaty applications: global gateway for Pharma and Biotech. (TBD)

Panel Discussion: New Trend of Pharmaceutical Patent Policy and Industry Demands

------- Core mechanism of the international drug patent system

------- Current situation and trend forecast of drug patent policy in China

------- Proposition of the pharmaceuticals industry

Networking Luncheon

Pharmaceutical R&D Innovation and IP Protection -- Global Vision

Intellectual Property Management Experience in Multinational Pharmaceutical Companies, Patent Layout Strategy, Litigation Strategy

PATENT INNOVATION: PATIENT VALUE FIRST

Hotspot Issues about Medicine Patent Litigation in China

Networking Coffee Break

Establishing The Internal Intellectual Property System under The New Legislative Landscape

Panel Discussion: Opportunities and Challenges of Pharmaceutical Enterprises under Patent Term Compensation System--- Global Vision and Its Implications for China

------- On January 4, 2019, Amendment to the patent law of the People's Republic of China (Draft) was published, which mentioned that "The State Council can decide to extend the patent term for the invention patent of innovative drugs that are synchronously applied for listing in China and abroad". New opportunities are opening up for new drug development in China.

------- Comparison of patent term compensation system between China and foreign countries

------- Opportunity or challenge under the new rules

Cocktail &NetworkingSponsorship Opportunities

The end of the first day

Case Sharing of Invalidity, Infringement, Litigation

Opening Address

Latest Changes in European Patent Application and Review Procedures

-------On March 12, 2019, the European Patent Office (EPO) released the 2018 annual report, which showed that the number of patent applications in China increased significantly, and the growth in life sciences was the fastest, and Chinese pharmaceutical companies reached a peak in the layout of Europe.The European Patent Office (EPO) has just published a new edition of Guidelines for Examination. The new guidelines will take effect from November 1, 2018.

Analysis of Hot Cases of Recent Patent invalidation

Europe and American Pharmaceutical Patent litigation and its Enlightenment to Chinese Pharmaceutical Enterprises (TBD)

------ Will Brexit change anything for litigation?

------ Planning a European/US strategy

Networking Coffee Break

Application techniques and protection strategies for European and American biomedical patents

------ Internal review procedures and application

------ Recent successful intellectual property strategies and possible problems

------ How can the intellectual property findings be effectively incorporated into the patent drafting process to ensure the legitimacy of U.S. courts?

------ American vision

Panel Discussion: European, American and Japanese Medical Patent Examination Cases and its implications for Domestic Pharmaceutical Companies ------- Various countries' review process and standards

------- Changes in standards for creative review of patents

------- Research on the standards of repeated authorization review

Networking Luncheon

Opportunities and challenges for generics companies under the new situation

Challenge Strategy and commercial value of Generic Drug Patents

The Strategy of Indian Generic Drug Companies in R&D and Pre-PA

Networking Coffee Break

Patent game in drug development

Recent Hot Patent Infringement Cases Analysis

------ With the advent of the patent cliff, the disputes increase between the primary drug companies and generic drug companies 

Panel Discussion:

The Strategy of Generic Drug Companies to Enter the European and American Markets

------- Various countries' review process and standards

------- Changes in standards for creative review of patents

------- Research on the standards of repeated authorization review

The end of the Conference & Chairman’s Closing Remarks

Lijingwan International Hotel
No. 28 Shilipu North, East 4Th Ring Road, Beijing, China
581
Register Now
Please call the conference committee at 86 21 65650305 or fill in the form. We will contact you as soon as possible